Small molecule tyrosine kinase inhibitors in glioblastoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Gayoung | - |
dc.contributor.author | Ko, Young Tag | - |
dc.date.available | 2020-05-20T00:35:20Z | - |
dc.date.created | 2020-04-14 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/43991 | - |
dc.description.abstract | Glioblastoma (GBM) is the most common malignant primary brain tumor, with poor survival despite treatment with surgery, radiotherapy, and chemotherapy with temozolomide. Little progress has been made over the last two decades, and there remain unmet medical needs. Approximately 45% of patients with GBM carry EGFR mutations, and 13% of them possess altered PDGFR genes. Moreover, VEGF/VEGFR mutations are also observed in the patient population. Tyrosine kinase inhibitors (TKIs) are emerging cancer therapy drugs that inhibit signal transduction cascades affecting cell proliferation, migration, and angiogenesis. Indications for small molecule TKIs have been successfully expanded to multiple types of cancer; however, none of the TKIs have been approved for patients with GBM. In this review, we summarize clinical trials of small molecule TKIs in patients with GBM and plausible hypotheses for negative clinical study results. We also discuss the potential TKI candidates that presented significant preclinical outcomes in patients with GBM. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.relation.isPartOf | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.title | Small molecule tyrosine kinase inhibitors in glioblastoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000522937000001 | - |
dc.identifier.doi | 10.1007/s12272-020-01232-3 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.identifier.kciid | ART002578698 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85082739119 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.contributor.affiliatedAuthor | Kim, Gayoung | - |
dc.contributor.affiliatedAuthor | Ko, Young Tag | - |
dc.type.docType | Review; Early Access | - |
dc.subject.keywordAuthor | Glioblastoma | - |
dc.subject.keywordAuthor | Brain tumor | - |
dc.subject.keywordAuthor | Small molecule drug | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | IMATINIB MESYLATE | - |
dc.subject.keywordPlus | BRAIN METASTASIS | - |
dc.subject.keywordPlus | EGFR INHIBITOR | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TEMOZOLOMIDE | - |
dc.subject.keywordPlus | GLIOMAS | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.